Covid-19 Drug Development

COVID-19 drugs are the development is the research process to develop preventative therapeutic prescription medicines that would alleviate the severity of corona virus disease 2019 (COVID-19). Many hundred pharmaceutical companies, biotechnology units, university research associations, and healthcare organizations are developing therapeutic students for COVID-19 disease in multiple stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials. Drug development is a multistep process, typically requiring more than five years to assure safety and efficacy of the new compound. Several national regulatory agencies, such as the EMA and the FDA, approved procedures to expedite clinical testing. Drug development is the process of bringing a new infectious disease vaccine or therapeutic drug to the market once a lead compound has been identified through the process of drug discovery.

  • Conducting clinical trials in a pandemic
  • Leverage innovative trial designs
  • Prophylactic design
  • New drug development paradigm

Related Conference of Covid-19 Drug Development

October 24-25, 2024

8th International Conference on Protein Engineering

Zurich, Switzerland

Covid-19 Drug Development Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in